ClinicalTrials.gg
RecruitingNCT07597018Updated Jun 26, 2026

A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

A Phase 1 interventional study of Cagrilintide D and Cagrilintide B and placebo semaglutide I in Obesity and Overweight, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Planned enrollment
17th of 36
234 · median 154
Started
2026
with 9 others
Phase 1
19 of 36
5 open now
Primary completion
2027-05
later than 3 of 14 live
Registered
30th of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 17th largest by planned enrollment, is one of 10 that started in 2026, is one of 19 in phase 1, reaches primary completion later than 3 of the 14 other live ones, and was the 30th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

This clinical study is testing two versions of the study medicine cagrilintide. The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity. Participants will receive either cagrilintide version D or cagrilintide version B, and which treatment participants receive is decided by chance. Participants will be in this clinical study for about 6 months.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-64 years (both inclusive) at the time of signing
  • (BMI) between 27.0 and 34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Previous participation in study(s) with an amylin analogue. Participation is defined as randomisation.
  • Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
234 participants (estimated)

Study arms

  • Experimental
    Cagrilintide B and Placebo Semaglutide I

    Participants will receive Cagrilintide B and Placebo semaglutide I subcutaneously once weekly for up to 17 weeks.

    Drug: Cagrilintide B and placebo semaglutide I

  • Experimental
    Cagrilintide D-Injection site 1

    Participants will receive Cagrilintide D subcutaneously once weekly for up to 17 weeks.

    Drug: Cagrilintide D

  • Experimental
    Cagrilintide D-Injection site 2

    Participants will receive Cagrilintide D subcutaneously once weekly for up to 17 weeks.

    Drug: Cagrilintide D

  • Experimental
    Cagrilintide D-Injection site 3

    Participants will receive Cagrilintide D subcutaneously once weekly for up to 17 weeks.

    Drug: Cagrilintide D

Interventions

  • Cagrilintide D will be administered subcutaneously.

  • DrugCagrilintide B and placebo semaglutide I

    Cagrilintide B and placebo semaglutide I will be administered subcutaneously

06

What researchers measure

Primary outcomes

  1. AUC,ss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide s.c.

    Measured in hour nanomoles per litre (h\*nmol/L)

    Time frame: Day 113 (pre-dose) to Day 120 (post-dose)

  2. Cmax,ss: maximum concentration of total cagrilintide at steady state after 5th dosing of cagrilintide s.c.

    Measured in nanomoles per litre (nmol/L).

    Time frame: Day 113 (pre-dose) to Day 120 (post-dose)

Secondary outcomes

  1. tmax,ss: time since last dosing to maximum concentration of totala cagrilintide at steady state after 5th dosing of cagrilintide s.c.

    Measured in hours.

    Time frame: Day 113 (pre-dose) to Day 120 (post-dose)

  2. t½,ss: terminal half-life of total cagrilintide at steady state after 5th dosing of cagrilintide s.c.

    Measured in hours.

    Time frame: Day 113 (pre-dose) to Day 162 (post-dose)

  3. Vz/F: the apparent volume of distribution of total cagrilintide during elimination after the 5th dosing of cagrilintide s.c.

    Measured in litre.

    Time frame: Day 113 (pre-dose) to Day 120 (post-dose)

  4. CL/F: total apparent clearance of total cagrilintide after the 5th dosing of cagrilintide s.c.

    Measured in litre per hours.

    Time frame: Day 113 (pre-dose) to Day 120 (post-dose)

  5. AUC,ss: area under the cagrilintide and metabolites concentration-time curve at steady state after the 5th dosing of cagrilintide s.c.

    Measured in hours\*nmol/L.

    Time frame: Day 113 (pre-dose) to Day 120 (post-dose)

  6. Cmax,ss: maximum concentration of cagrilintide and metabolites at steady state after the 5th dosing of cagrilintide s.c.

    Measured in nmol/L.

    Time frame: Day 113 (pre-dose) to Day 120 (post-dose)

  7. tmax,ss: time since the last dosing to maximum concentration of cagrilintide and metabolites at steady state after the 5th dosing of cagrilintide s.c.

    Measured in hours.

    Time frame: Day 113 (pre-dose) to Day 120 (post-dose)

  8. t½,ss: terminal half-life of cagrilintide parent at steady state after the 5th dosing of cagrilintide s.c.

    Measured in hours.

    Time frame: Day 113 (pre-dose) to Day 120 (post-dose)

  9. AUC,ss: area under the total cagrilintide concentration-time curve at steady state after the 4th dosing of cagrilintide s.c

    Measured in hours\*nmol/L.

    Time frame: Day 22 (pre-dose) to Day 29 (post-dose)

  10. Cmax,ss: maximum concentration of total cagrilintide at steady state after the 4th dosing of cagrilintide s.c.

    Measured in nmol/L.

    Time frame: Day 22 (pre-dose) to Day 29 (post-dose)

  11. tmax,ss: time since the last dosing to maximum concentration of total cagrilintide at steady state after the 4th dosing of cagrilintide s.c.

    Measured in hours.

    Time frame: Day 22 (pre-dose) to Day 29 (post-dose)

  12. Number of treatment-emergent adverse events (TEAEs)

    Measured in count of events.

    Time frame: Day 1 (randomisation) to Day 162 (end of study)

  13. Number of treatment-emergent serious adverse events (TESAEs)

    Measured in count of events.

    Time frame: Day 1 (randomisation) to Day 162 (end of study)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 12 months is above that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 19, 2026
StartActual
May 18, 2026
Primary completionEst.
May 28, 2027
CompletionEst.
Jun 1, 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07597018
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 19, 2026
Start date
May 18, 2026
Primary completion
May 28, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jun 26, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion